These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 22632451)

  • 21. Cost-effectiveness of systemic treatments for moderate-to-severe psoriasis in the German health care setting.
    Küster D; Nast A; Gerdes S; Weberschock T; Wozel G; Gutknecht M; Schmitt J
    Arch Dermatol Res; 2016 May; 308(4):249-61. PubMed ID: 26961372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Costs of therapy with biologics in the treatment of moderate to severe plaque psoriasis in the context of the Italian health-care system.
    Terranova L; Mattozzi C; Richetta AG; Mantuano M; Cardosi L; Teruzzi C
    G Ital Dermatol Venereol; 2014 Feb; 149(1):131-43. PubMed ID: 24566574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Efficiency of biologic agents in the treatment of moderate to severe psoriasis].
    Blasco AJ; Lázaro P; Ferrándiz C; García-Díez A; Liso J
    Actas Dermosifiliogr; 2009 Nov; 100(9):792-803. PubMed ID: 19889301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece.
    Avgerinou G; Bassukas I; Chaidemenos G; Katsampas A; Kosmadaki M; Kousoulakou H; Petridis A; Schenkel B; Sotiriadis D; Spiliopoulos T; Stavropoulos P; Toumpi E; Xaplanteris L
    BMC Dermatol; 2012 Jul; 12():10. PubMed ID: 22831458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.
    Armstrong AW; Betts KA; Signorovitch JE; Sundaram M; Li J; Ganguli AX; Wu EQ
    Curr Med Res Opin; 2018 Jul; 34(7):1325-1333. PubMed ID: 29619856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Model for assessing the efficiency of biologic drugs in the treatment of moderate to severe psoriasis for one year in clinical practice in Spain.
    Puig L; López-Ferrer A; Vilarrasa E; García I; Fernández-del Olmo R
    Actas Dermosifiliogr; 2016; 107(1):34-43. PubMed ID: 26365029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological treatments for moderate-to-severe psoriasis: indirect comparison.
    Galván-Banqueri M; Marín Gil R; Santos Ramos B; Bautista Paloma FJ
    J Clin Pharm Ther; 2013 Apr; 38(2):121-30. PubMed ID: 23442134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A retrospective observational study on biological drug treatment in a daily practice serving patients with psoriasis in Japan.
    Ohata C; Ohyama B; Nanri A; Shintani T; Nakama T
    J Dermatolog Treat; 2019 Feb; 30(1):45-48. PubMed ID: 29676591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biologics in the treatment of psoriasis: clinical and economic overview.
    Poulin Y; Langley RG; Teixeira HD; Martel MJ; Cheung S
    J Cutan Med Surg; 2009; 13 Suppl 2():S49-57. PubMed ID: 19799827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.
    Schmitt J; Zhang Z; Wozel G; Meurer M; Kirch W
    Br J Dermatol; 2008 Sep; 159(3):513-26. PubMed ID: 18627372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Scalp psoriasis and biologic agents: a retrospective, comparative study from a tertiary psoriasis referral centre.
    Fotiadou C; Lazaridou E; Sotiriou E; Kyrgidis A; Apalla Z; Ioannides D
    J Eur Acad Dermatol Venereol; 2016 Dec; 30(12):2091-2096. PubMed ID: 27406435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N; Lee YC; Shah N; Harrison DJ
    Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis.
    D'Souza LS; Payette MJ
    J Am Acad Dermatol; 2015 Apr; 72(4):589-98. PubMed ID: 25631851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.
    Aliyev ER; Hay JW; Hwang C
    Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adalimumab for the treatment of psoriasis.
    Turner D; Picot J; Cooper K; Loveman E
    Health Technol Assess; 2009 Sep; 13 Suppl 2():49-54. PubMed ID: 19804689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis.
    Martin S; Feldman SR; Augustin M; Szapary P; Schenkel B
    J Dermatolog Treat; 2011 Jun; 22(3):138-43. PubMed ID: 21254886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.
    Johansson EC; Hartz S; Kiri SH; Kumar G; Svedbom A
    J Med Econ; 2018 Aug; 21(8):810-820. PubMed ID: 29873270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biologic Therapy for Ulcerative Colitis.
    Bhattacharya A; Osterman MT
    Gastroenterol Clin North Am; 2020 Dec; 49(4):717-729. PubMed ID: 33121691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.
    Sawyer LM; Cornic L; Levin LÅ; Gibbons C; Møller AH; Jemec GB
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):355-366. PubMed ID: 30289198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials].
    Zhang Z; Schmitt J; Wozel G; Kirch W
    Med Klin (Munich); 2009 Feb; 104(2):125-36. PubMed ID: 19242664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.